Disease Information

General Information of the Disease (ID: DIS00193)

• Name: B cell lymphoma
• ICD: ICD-11: 2A86

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Rituximab

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: B-lymphocyte antigen CD20 (CD20) [1]

• Resistant Disease: B cell lymphoma [ICD-11: 2A86.1]
• Molecule Alteration: Expression; Up-regulation
• Resistant Drug: Rituximab
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Obviously, the CD20 molecule itself can be involved in resistance to Rituximab by loss in protein expression, membrane exposure and structural changes. Reduction or loss of CD20 cell surface expression following Rituximab treatment has been reported in some patients with B-NHL.

References

• Ref 1: Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention .Leuk Lymphoma. 2009 Jun;50(6):873-85. doi: 10.1080/10428190902878471. 10.1080/10428190902878471